B-cell development

Last updated: November 01, 2022

B-cell development

Watch later

Watch later

Action potentials in myocytes
Action potentials in pacemaker cells
Excitability and refractory periods
Cardiac excitation-contraction coupling
Antidiuretic hormone
Calcitonin
Phosphate, calcium and magnesium homeostasis
Vitamin D
Blood components
Innate immune system
Complement system
Cytokines
T-cell development
B-cell development
MHC class I and MHC class II molecules
T-cell activation
B-cell activation, differentiation, and contraction
Cell-mediated immunity of CD4 cells
Cell-mediated immunity of natural killer and CD8 cells
B- and T-cell memory
Type I hypersensitivity
Type II hypersensitivity
Type III hypersensitivity
Type IV hypersensitivity
Bone remodeling and repair
Muscular system anatomy and physiology
Neuromuscular junction and motor unit
Slow twitch and fast twitch muscle fibers
Muscle spindles and golgi tendon organs
Muscle contraction
Sliding filament model of muscle contraction
Nervous system anatomy and physiology
Neuron action potential
Adrenergic receptors
Sympathetic nervous system
Parasympathetic nervous system
Cholinergic receptors
Body fluid compartments
Movement of water between body compartments
Hydration
Renin-angiotensin-aldosterone system
Sodium homeostasis
Potassium homeostasis
Osmoregulation
Necrosis and apoptosis
Hypoxia
Ischemia
Inflammation
Wound healing
Oncogenes and tumor suppressor genes
Hyperplasia and hypertrophy
Atrophy, aplasia, and hypoplasia
Metaplasia and dysplasia
Pharmacodynamics: Drug-receptor interactions
Enzyme function
Pharmacodynamics: Agonist, partial agonist and antagonist
Pharmacodynamics: Desensitization and tolerance
Pharmacokinetics: Drug absorption and distribution
Pharmacokinetics: Drug elimination and clearance
Pharmacokinetics: Drug metabolism
Cholinomimetics: Direct agonists
Muscarinic antagonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Sympathomimetics: Direct agonists
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Presynaptic
Adrenergic antagonists: Alpha blockers
Adrenergic antagonists: Beta blockers
Anticoagulants: Heparin
Anticoagulants: Warfarin
Monoclonal antibodies
Glucocorticoids
Cell wall synthesis inhibitors: Penicillins
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Fluoroquinolones
Antimetabolites: Sulfonamides and trimethoprim
DNA synthesis inhibitors: Metronidazole
Mechanisms of antibiotic resistance
Protein synthesis inhibitors: Aminoglycosides
Miscellaneous cell wall synthesis inhibitors
Integrase and entry inhibitors
Protease inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Azoles
Miscellaneous antifungal medications
Echinocandins
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Parathyroid conditions and calcium imbalance: Clinical
Parathyroid disorders and calcium imbalance: Pathology review
DNA replication
Transcription of DNA
DNA mutations
Translation of mRNA
Proteins
Resting membrane potential
Demyelinating disorders: Pathology review
Blood groups and transfusions
Microcirculation and Starling forces
Bacterial structure and functions
Staphylococcus epidermidis
Staphylococcus aureus
Staphylococcus saprophyticus
Streptococcus pneumoniae
Clostridium perfringens
Clostridium botulinum (Botulism)
Clostridium tetani (Tetanus)
Clostridium difficile (Pseudomembranous colitis)
Escherichia coli
Salmonella (non-typhoidal)
Enterobacter
Shigella
Vibrio cholerae (Cholera)
Campylobacter jejuni
Mycoplasma pneumoniae
Viral structure and functions
Varicella zoster virus
Human herpesvirus 8 (Kaposi sarcoma)
Epstein-Barr virus (Infectious mononucleosis)
Herpes simplex virus
Human herpesvirus 6 (Roseola)
Adenovirus
Human papillomavirus
Rhinovirus
Influenza virus
Norovirus
Rotavirus
Vaccinations
Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review
Immunodeficiencies: T-cell and B-cell disorders: Pathology review
Immunodeficiencies: Phagocyte and complement dysfunction: Pathology review
Introduction to the lymphatic system
Mendelian genetics and punnett squares
Inheritance patterns
Muscular dystrophies and mitochondrial myopathies: Pathology review
Autosomal trisomies: Pathology review
Miscellaneous genetic disorders: Pathology review
Independent assortment of genes and linkage
DNA structure
Nuclear structure
Amino acids and protein folding
Gene regulation
Lac operon
Karyotyping
Gel electrophoresis and genetic testing
Polymerase chain reaction (PCR) and reverse-transcriptase PCR (RT-PCR)
DNA cloning
Down syndrome (Trisomy 21)
Huntington disease
Williams syndrome
Cystic fibrosis
Glycogen storage disease type I
Glycogen storage disease type II (NORD)
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Deep vein thrombosis
Deep vein thrombosis and pulmonary embolism: Pathology review
Immunodeficiencies: Clinical
Selective immunoglobulin A deficiency
Isolated primary immunoglobulin M deficiency
Dermatomyositis
Crohn disease
Complement deficiency
Lupus nephritis
Thymus histology
Lymph node histology
Spleen histology
Respiratory alkalosis

Transcript

Watch video only

Your immune system is like the military - with two main branches, the innate immune response and the adaptive immune response.

The innate immune response is immediate and non-specific, meaning that although it can distinguish an invader from a human cell, it doesn’t distinguish one invader from another invader.

In contrast, the adaptive immune response is highly specific for each invader, and that’s because the cells of the adaptive immune response have receptors that differentiate friendly bacteria and potentially deadly ones from their unique parts - called antigens.

This adaptive immune response takes days to weeks to become activated, but is also responsible for immunologic memory.

Now, the key cells of the adaptive immune response are the lymphocytes- the B and T cells -which are generated during lymphopoiesis.

Lymphopoiesis has three goals - first, to generate a diverse set of lymphocytes - each with a unique antigen receptor, second, to get rid of lymphocytes that have receptors that are self-reactive meaning that they’ll bind to healthy tissue, and third, to allow lymphocytes that aren’t self-reactive to continue maturing in secondary lymphoid tissue.

Normally, hematopoietic stem cells, within the bone marrow mature into a common lymphoid progenitor cell, which then becomes either a B-cell or a T-cell.

To become a B cell, it has to develop into an immature B-cell in the bone marrow and then complete its maturation into an antibody secreting B cell, called a plasma cell, in the lymph nodes and spleen.

To become a T cell, it has to migrate to the thymus and become a thymocyte, where it completes its development into a mature T cell.

So, “B” for bone marrow and “T” for thymus.

Throughout B cell development, the developing cells are interacting closely with the stromal cells of the bone marrow, which are largely composed of mesenchymal stem cells.

Mesenchymal cells are multipotent and can differentiate into various cells including macrophages and endothelial cells.

Mesenchymal cells provide B cell with adhesion molecules they can use to attach and important growth factors like interleukin 7, they can use to grow and proliferate.

As they develop, B cells go through 6 stages: They start as common lymphoid progenitor cells, then become early pro-B cells, then late pro-B cells, then large pre-b cells, then small pre-B cells, and finally immature B cells.

As the cell develops it makes permanent changes in its DNA so that by the time it’s an immature B cell it has DNA that uniquely codes for a B cell receptor that can bind to foreign antigens but isn’t self-reactive.

The B cell receptor has two chains, a heavy chain and a light chain.

The heavy chain contains regions that determine the type of antibody it will become as well as whether the B cell receptor will be surface bound or secreted, like an antibody.

The region where the heavy chain and light chain come together form a unique protein structure capable of binding proteins, carbohydrates, or lipids that the B cell might eventually encounter - and this is called the antigen binding site.

The antigen binding site of the B cell receptor is made up of three protein segments that are called V for variable, D for diversity, and J for joining.

The heavy chain is made up of 1 V segment, 1 D segment, and 1 J segment; while the light chain only contains a V and J segment - this is easy to remember - just think of it as the extra segment making the heavy chain heavier.

Every person inherits multiple genes that encode the V, D, and J protein segments, and these segments can be mixed and matched to make a unique structure.

A bit like how you might have several pairs of shoes, pants, and shirts and can mix and match them to create lots of different outfit combinations.

For the heavy chain, each person has 44 V gene segments, 27 D segments, and 6 J segments! And there are even more V and J segments for the light chain.

So one B cell might have a B cell receptor with a heavy chain that has a VH1-DH3-JH5 combination and a light chain that’s VL7-JL2, and another B cell might have a B cell receptor with a heavy chain that has a VH44-DH10-JH1 combination and a light chain that’s VL2-JL3.

And that would mean that these two B-cells would have completely different B cell receptors and therefore different antigen specificities.

Now, to have a fully functioning B cell receptor, a B cell has to get through a series of successful gene rearrangements, first for the heavy chain and then the light chain. And if the B cell fails at any stage, it dies!

It all starts with a common lymphoid progenitor cell which has various V, D, and J gene segments all lined up in its germline DNA.

Two enzymes, Rag-1 and Rag-2, start getting expressed, and that signifies that the cell is now an early pro-B cell.

Rag-1 and Rag-2 help to splice together D and J segments on both chromosomes, and the chromosome that successfully rearranges first will then suppress the other chromosome from rearranging - a process called allelic exclusion.

If a cell successfully joins a D segment to a J segment, then it’s considered a late pro-B cell.

Next, the late pro-B cell has to attach its D-J gene segment to a V gene segment, with the help of an additional enzyme called V(D)J recombinase.

Once the VDJ segment are combined, the full heavy chain’s antigen binding site is complete and needs to be recombined with the mu gene, which codes for the constant region of the antibody. T

he mu gene codes for the protein that makes the IgM constant region and it’s the first of the different types of antibody constant regions that are expressed on B cells.

Key Takeaways

B-cell development consists of a series of cellular transitions, from hematopoietic stem cells into immunocompetent B cells. Depending on the step, these processes take place in different organs namely the bone marrow, lymph nodes, and spleen.

Like any other type of blood cell, B cells originate from hematopoietic stem cells (HSCs). HSCs give rise to common lymphoid progenitor cells, which in their turn become either B-cells or T-cells. B cell development takes place in a series of six main stages. First, they start as common lymphoid progenitor cells, which become early pro-B cells, then late pro-B cells, next large pre-B cells, then small pre-B cells, and finally, immature B cells. Immature B cells then migrate from the bone marrow into the lymph nodes and spleen to complete the process of maturation.